Creekwood FDA Tuesday, April 7, 2026 0.00 Neutral

FDA Approves NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) — Creekwood Pharmaceuticals LLC

# FDA Approves Creekwood Pharmaceuticals' Generic Nitrofurantoin for Urinary Tract Infections The FDA has approved Creekwood Pharmaceuticals LLC's generic nitrofurantoin monohydrate/macrocrystals oral formulation, expanding treatment options in the competitive urinary tract infection market and potentially increasing pricing pressure on incumbent suppliers. The approval of the ANDA application could capture additional market share in the established antibiotic segment while offering patients more affordable alternatives.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day